Beam Therapeutics announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.
Public source
Publisher name
Public post
Today, Beam announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency. Beam will host a conference call and webcast…
Company
Beam Therapeutics
Our vision is to provide life-long cures for patients suffering from serious diseases.
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 501–1,000 employees
About Beam Therapeutics
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
See moreLatest activity
Latest activity from Beam Therapeutics
9 signals
Presence & Recognition
Beam Therapeutics will host a conference call and webcast today at 7:00 a.m. ET to review updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.
Research & Knowledge
Beam Therapeutics shared updated clinical data from the BEAM-302 program for alpha-1 antitrypsin deficiency, demonstrating durable correction of the disease-causing mutation, increased total and functional AAT, reduced mutant Z-AAT and toxic Z-polymers, and evidence that AAT production remains under normal physiologic control.
People
Beam Therapeutics is currently hiring across multiple functions.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Precision BioSciences, Inc.
Precision BioSciences, Inc. reported that the first participant in the FUNCTION-DMD clinical trial received an investigational gene-editing treatment, PBGENE-DMD, designed to permanently address the underlying cause of Duchenne muscular dystrophy.
Research & Knowledge
Fortrea
Fortrea published results from an early-stage trial showing that a single-dose experimental gene-editing therapy reduced bad cholesterol and triglycerides in patients for at least one year.
Research & Knowledge
Wave Life Sciences
Wave Life Sciences presented interim results from RestorAATion-2, an ongoing clinical trial of WVE-006 for alpha-1 antitrypsin deficiency, at the ERSCongress poster session.
Research & Knowledge
Ultragenyx
Ultragenyx published additional analyses from its Phase 3 GlucoGene study of gene therapy to treat glycogen storage disease type Ia in The Journal of Inherited Metabolic Disease.
Products & Services
Scribe Therapeutics